Postoperative survival of pulmonary invasive mucinous adenocarcinoma versus non-mucinous invasive adenocarcinoma

• Published in: BMC pulmonary medicine Vol. 23; no. 1; p. 9
• Main Authors: Cui, Dongyu, Xie, Shaonan, Liu, Qingyi
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 09.01.2023; BioMed Central; BMC
• Subjects: Adenocarcinoma - pathology; Adenocarcinoma of Lung - pathology; Adenocarcinoma of Lung - surgery; Adenocarcinoma, Mucinous - pathology; Adenocarcinoma, Mucinous - surgery; Analysis; Care and treatment; Diagnosis; Gene mutations; Genetic aspects; Health aspects; Humans; Lung - pathology; Lung cancer; Lung Neoplasms - pathology; Lung Neoplasms - surgery; Metastasis; Mucinous adenocarcinoma; Neoplasm Staging; NSCLC; Patient outcomes; Prevention; Prognosis; Propensity score matching; Propensity scores; Radiotherapy; Retrospective Studies; Risk factor; Risk factors; China; Propensity score matching; Prognosis; Mucinous adenocarcinoma; NSCLC; Risk factor
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-023-02305-x

In 2015, the World Health Organization renamed mucinous bronchioloalveolar adenocarcinoma as pulmonary invasive mucinous adenocarcinoma (IMA). Due to its low incidence and unclear prognosis with surgical treatment, previous studies have presented opposing survival outcomes. We aimed to investigate the differences in surgical prognosis and prognosis-related risk factors by comparing IMA with non-mucinous invasive adenocarcinoma (NMA). A total of 20,914 patients diagnosed with IMA or NMA from 2000 to 2014 were screened from the Surveillance, Epidemiology, and End Results database. The screened patients were subjected to propensity score matching (PSM) in a 1:4 ratio to explore the survival differences between patients with IMA and NMA and the factors influencing prognosis. For all patients, IMA was prevalent in the lower lobes of the lungs (p < 0.0001), well-differentiated histologically (p < 0.0001), less likely to have lymph node metastases (94.4% vs. 72.0%, p < 0.0001) and at an earlier pathological stage (p = 0.0001). After PSM, the IMA cohort consisted of 303 patients, and the NMA cohort consisted of 1212 patients. Kaplan‒Meier survival analysis showed no difference in overall survival (OS) between patients in the IMA cohort and those in the NMA cohort (p = 0.7). Cox proportional hazards analysis showed that differences in tumor pathological type did not influence OS between the two cohorts (p = 0.65). Age (HR: 1.98, 95% CI 1.7-2.31, p < 0.0001), gender (HR: 0.64, 95% CI 0.55-0.75, p < 0.0001), and radiation treatment (HR: 2.49, 95% CI 1.84-3.37, p < 0.0001) were independent predictors of patient OS. There was no significant difference in OS between patients with IMA and those with NMA after surgical treatment. Age, sex, and radiation treatment can independently predict OS.